Learning life skills to handle Duchenne muscular dystrophy can include health management, working with caregivers, and ...

A new article argues dystrophin immunogenicity is an under-examined issue in the treatment of Duchenne muscular dystrophy.

Duchenne Muscular Dystrophy: diagnosis, clinical development and global researchMuscular dystrophy refers to a group of rare, genetic, progressive diseases that primarily affect the body’s muscles, ...

A major trial of a promising gene therapy for Duchenne muscular dystrophy has fallen short, but researchers say the lessons learned could pave the way for better, more effective treatments.

Two dose levels of a single-administration gene therapy were well-tolerated and led to functional improvements in ambulatory ...

None of the eteplirsen-treated patients reached a left ventricular ejection fraction below 50% compared with 22.1% of patients in the control group.

Doing more to incorporate caregiver burden into value assessments and cost-effectiveness research of Duchene muscular ...

Patients in Scotland can't get the treatment - which is available in England - despite manufacturers giving it away for free ...

Pratteln, Switzerland, April 16, 2025 – Santhera Pharmaceuticals (SIX: SANN) announces the latest progress on the commercial rollout of AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD).

Keros Therapeutics halted phase 2 of TROPOS, but KER-065 shows promise in DMD and financial stability ensures growth ...

One day after the European Medicines Agency requested that three clinical trials of Elevidys be placed on hold after the ...